Literature DB >> 2424650

The human IgA system: a reassessment.

J Mestecky, M W Russell, S Jackson, T A Brown.   

Abstract

In healthy adults the total daily production of secretory and serum IgA exceeds that of other immunoglobulin classes. Secretory and serum IgA display features of mutual independence: they are represented by molecules with different physiochemical and immunochemical properties and antibody activities and are produced by cells with different organ distributions. Secretory and serum IgA also exhibit different effector functions: interaction of secretory IgA with environmental antigens results in prevention of the penetration of such antigens by a variety of mechanisms. Although the function of polymeric serum IgA antibodies in certain animal species involves elimination of antigenic substances by noninflammatory means, the primary function of serum IgA remains unknown. It is proposed that in humans monomeric serum IgA (which prevents activation of the complement systems, inhibits phagocytosis and antibody-dependent cellular cytotoxicity) may protect endogenous antigens expressed on various cells and tissues by preventing their interaction with humoral and cellular immune mechanisms that may lead to tissue damage.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424650     DOI: 10.1016/0090-1229(86)90073-5

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  56 in total

Review 1.  Progress in molecular and genetic studies of IgA nephropathy.

Authors:  J Novak; B A Julian; M Tomana; J Mesteck
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

2.  Secretory IgA are elevated in both saliva and serum of patients with various types of primary glomerulonephritis.

Authors:  G Rostoker; H Terzidis; M Petit-Phar; D Meillet; P Lang; J M Dubert; G Lagrue; B Weil
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

3.  Mucosal and systemic IgA anti-gliadin antibody in celiac disease. Contrasting patterns of response in serum, saliva, and intestinal secretions.

Authors:  C P Kelly; C F Feighery; R B Gallagher; M J Gibney; D G Weir
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

4.  IgA1 is the major immunoglobulin component of immune complexes in the acquired immune deficiency syndrome.

Authors:  S Jackson; L M Dawson; D P Kotler
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

5.  Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine.

Authors:  B D Forrest
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

6.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

7.  IgG and IgA enhance the chrysotile-induced production of reactive oxygen metabolites by human polymorphonuclear leucocytes.

Authors:  M Klockars; M Hedenborg; J Koistinen; T Isobe
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

8.  The gut as an inductive site for synovial and extra-articular immune responses in rheumatoid arthritis.

Authors:  C Trollmo; C Sollerman; H Carlsten; A Tarkowski
Journal:  Ann Rheum Dis       Date:  1994-06       Impact factor: 19.103

9.  Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response.

Authors:  C Lue; A W van den Wall Bake; S J Prince; B A Julian; M L Tseng; J Radl; C O Elson; J Mestecky
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

10.  IgA subclass antibodies to gliadin in serum and intestinal juice of patients with coeliac disease.

Authors:  U Volta; N Molinaro; D Fratangelo; F B Bianchi
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.